Oral chemotherapy: Rationale and future directions

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2557-2567

  DeMario, Mark D ^a   Ratain, Mark J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; 9 AMINOCAMPTOTHECIN; ALKYLATING AGENT; ANTIMETABOLITE; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 ISOENZYME; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GLYCOPROTEIN P; HYDROXYUREA; IRINOTECAN; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; NAVELBINE; PLATINUM DERIVATIVE; PROCARBAZINE; SATRAPLATIN; TEGAFUR; TIOGUANINE; TOPOTECAN; UFT; UNINDEXED DRUG; URACIL DERIVATIVE; VINCA ALKALOID;

AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MIXTURE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0031859489     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2557     Document Type: Review

References (128)

1. Reinhardt U: Revitalizing the American Health Care System. Internal Medicine World Report. Medical World Business Press, Inc, 1989
2. Brown ML: The national economic burden of cancer: An update. J Natl Cancer Inst 82:1811-1814, 1990
3. Friedlander ML, Tattersall MHN: Counting costs of cancer therapy. Eur J Cancer Clin Oncol 18:1237-1241, 1982
4. Projections of National Health Care Expenditures. Washington, DC, Congressional Budget Office, 1992
5. Brown ML, Nayfield SG, Shibley LM: Adjuvant therapy for stage III colon cancer: Economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 86:424-430, 1994
6. Jaakkimainen L, Goodwin PJ, Pater P, et al: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 8:1301-1309, 1990
7. Hillner BE, Smith TJ, Desch CE: Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model. Breast Cancer Res Treat 25:97-105, 1993
8. Glimelius B, Hoffman K, Graf W, et al: Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 6:267-274, 1995
9. Cowan DH: The effect of medicare reimbursement policies on the cost and setting of cancer chemotherapy. Cancer Invest 14:184-186, 1996
10. Lokich JJ, Moore CL, Anderson NR: Comparison of costs for infusion versus bolus chemotherapy administration - Part II. Cancer 78:300-303, 1996
11. Davies L, Maynard A: An economic exploration of oral and intravenous ganciclovir in the induction and maintenance treatment of AIDS-related cytomegalovirus retinitis. Int J STD AIDS 7:415-421, 1996
12. Sullivan SD, Mozaffari E, Johnson ES, et al: An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Clin Therapeut 18:546-558, 1996
13. Liu G, Franssen E, Fitch M, et al: Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997
14. Hande KR, Krozely MG, Greco FA, et al: Bioavailability of low dose oral etoposide. J Clin Oncol 11:374-377, 1993
15. Smyth, RD, Pfeffer M, Scalzo A, et al: Bioavailability and pharmacokinetics of etoposide (VP16). Semin Oncol 12:48-51, 1985 (suppl 2)
16. McGuire B, Sia L, Haynes J, et al: Absorption kinetics of orally administered leucovorin calcium. NCI Monogr 5:47-56, 1987
17. Joel SP, Clark PI, Heap L, et al: Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother Pharmacol 37:125-133, 1995
18. Hellreiegel ET, Bjornsson TD, Hauck WW: Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 60:601-607, 1996
19. Harvey VJ, Slevin M, Joel SP, et al: Variable bioavailability following repeated doses of etoposide. Eur J Cancer Clin Oncol 21:1315-1319, 1985
20. Hassan M, Ljungman P, Bolme P et al: Busulfan bioavailability. Blood 84:2144-2150, 1994
21. Lebbe C, Beyeler C, Gerber N, et al: Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 53:475-477, 1994
22. Zimm S, Collins JM, Riccardi R, et al: Variable bioavailability of oral mercaptopurine: Is maintenance chemotherapy in ALL being optimally delivered? N Engl J Med 308:1005-1009, 1983
23. Watkins PB, Wrighton SA, Maurel P, et al: Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 82:6310-6314, 1985
24. Kolars JC, Schmeidlin-Ron J, Scheutz M, et al: Expression of P450IIIA4 in duodenal mucosa: Interpatient variability and regulation in cultured expiants. Gastroenterology 100:A221, 1991 (abstr)
25. Kolars JC, Awni W, Merion R, et al: First pass metabolism of cyclosporine by the gut. Lancet 338:1488-1490, 1991
26. Chang TK, Weber GF, Crespi CL, et al: Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637, 1993
27. Relling MV, Nemec J, Schuetz E, et al: O-demetheylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3 A4. Mol Pharmacol 45:352-358, 1994
28. Wacher MJ, Chi-Yuan W, Benet LZ: Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 13:129-134, 1995
29. Toffoli G, Simone F, Gigante M, et al: Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resisitant LoVo cell lines. Biochem Pharmacol 48:1871-1881, 1994
30. Harris JW, Rahman A, Bok-Ryang K, et al: Metabolism of Taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and and unknown P450 enzyme. Cancer Res 54:4026-4035, 1994
31. Hendricks C, Rowinsky E, Grochow L , et al: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK & F 104864), a new camptothecin analogue. Cancer Res 52:2268-2278, 1992
32. Zhou X, Rahmani R : Preclinical and clinical pharmacology of vinca alkaloids Drugs 44:1-16, 1992 (suppl 4)
33. Adams D, Knick V: P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). Invest New Drugs 13:13-21, 1995
34. Kobayashi K, Ratain MJ, Fleming GF, et al: A phase I study of CYP3A4 modulation of oral etoposide with ketoconazole in patients with advanced cancer. Proc Am Soc Cin Oncol 15:471, 1996 (abstr 1489)
35. Guengerich, FP: Characterization of human cytochrome P450 enzymes. FASEB J 6:745-748, 1992
36. Lown, KS, Kolars JC, Thummel KE, et al: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22:947-955, 1994
37. Schuetz E, Schuetz J, Strom S, et al: Regulation of human liver cytochromes P-450in family 3A in primary and continuous culture of human hepatocytes. Hepatology 18:1254-1262, 1993
38. Jacolot F, Simon I, Dreano Y, et al: Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41:1911-1919, 1991
39. Guengerich F, Muller-Enoch D, Blair I: Oxidation of quinidine by human liver cytochrome P450. Mol Pharmacol 30:287-295, 1986
40. Zhou-Pan XR, Seree E, Zhou XJ, et al: Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions. Cancer Res 53:5121-5126, 1993
41. Herbert MF, Roberts JP, Prueksaritanost T, et al: Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clinical Pharmacol Ther 52:453-457, 1992
42. Gupta SK: Erythromycin enhances the absorption of cyclosporine. Br J Clin Pharmacol 25:401-402, 1988
43. Gomez DY, Wacher VJ, Tomlanovich SJ, et al: The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19, 1995
44. Keogh A, Spratt P, McCosker C, et al: Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 333:628-633, 1995
45. Thiebaut F, Tsuruo T, Hamada H, et al: Cellular localization ot the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738, 1987
46. Wils P, Phung B, Warney A, et al: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48:1528-1530, 1994
47. Sparreboom A, Van Asperen J, Mayer U, et al: Limited oral bioavailability and active epithelial excretion of pacllitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035, 1997
48. Leu BL, Huang JD: Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 35:432-436, 1995
49. Van Asperen J, Van Tellingen O, Sparreboom A, et al: Enhanced oral bioavailability of paclitaxel in mice treated wtih the P-glycoprotein blocker SDZ PSC 833 or cyclosporin A. Proc Am Soc Cancer Res 38:5, 1997 (abstr 33)
50. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981
51. Lebovits AH, Strain J, Schleifer SJ, et al: Patient noncompliance with self administered chemotherapy. Cancer 65:17-22, 1990
52. Levine AM, Richardson JL, Marks G, et al: Compliance with oral drug therapy in patients with hematologic malignancy J Clin Oncol 5:1469-1476, 1987
53. Richardson JL, Marks G, Levine AM: The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 6:1746-1752, 1988
54. Lee CR, Nicholson PW, Souhami RL, et al: Patient compliance with oral chemotherapy as assessed by a novel oral technique. J. Clin Oncol 10:1007-1013, 1992
55. Lee C, Nicholson P, Souhami R, et al: Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer 67:630-634, 1993
56. Abernethy DR, Alper JC, Wiemann, MC, et al: Oral 5-fluorouracil in psoriasis: Pharmacokinetic-pharmacodynamic relationships. Pharmacology 39:78-88, 1989
57. Cohen JL, Irwin LE, Marshall GJ, et al: Clinical pharmacology of oral and intravenous 5- fluorouracil. Cancer Chemother Rep 58:723-731, 1974
58. Finch, RE, Bending, MR, Lant AF: Plasma levels of 5-FU after oral and intravenous administration in cancer patients. Br J Pharmacol 7:613-617, 1979
59. Phillips TA, Howell A, Grieve R, et al: Pharmacokinetics of oral and intravenous fluorouracil in humans. J Pharm Sci 69:1428-1431, 1980
60. Christophidis N, Vajda FJE, Lucas I, et al: Fluorouracil therapy in patients with carcinoma of the large bowel: A pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet 3:330-336, 1978
61. Baker SD, Khor SP, Adjei AA, et al: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14:3085-3096, 1996
62. Antilla MI, Sotaniemi EA, Kairaluoma MI, et al: Pharmacokinetics of Ftorafur after i.v. and oral administration. Cancer Chemother Pharmacol 10:150-153, 1983
63. Friedman MA, Ignoffo RS: A review of the U.S. clinical experience of the fluoro- pyrimidine, ftorafur. Cancer Treat Rev 7:205-213, 1980
64. Byfield JE, Hornbeck CL, Frankel SS, et al: Relevance of the pharmacology of oral tegafur to its use as a 5-fluorouracil prodrug. Cancer Treat Rep 69:645-652, 1985
65. Au JL, Wu AT, Friedman MA, et al: Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep 63: 343-350, 1979
66. Ishitsuka H, Miwa M, Ishikawa T, et al: Capecitabine: An orally available fluoropyrimidine with tumor selective activity. Proc Am Assoc Cancer Res 36:407, 1995 (abstr)
67. Poplack DG, Balis FM, Zimm S: The pharmacology of orally-administered chemotherapy: A reappraisal. Cancer 58:473-480, 1986
68. Zimm S, Collins JM, Oneill D, et al: Inhibition of first-pass metabolism in cancer chemotherapy: Interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 34: 810-817, 1983
69. Product Information, Tabloid brand Thioguanine, GlaxoWellcome, Research Triangle Park, NC, 1994
70. Reynolds JEK (ed): The Extra Pharmacopoeia. Denver, CO, Micromedex, Martindale, 1994
71. McEvoy GK (ed): American Hospital Formulary Service: Drug Information. Bethesda, MD, American Society Hospital Pharmacists, 1993
72. Bleyer WA: The clinical pharmacology of methotrexate: New applications of an old drug. Cancer 41:36-51, 1978
73. Product Information, Methotrexate, Laboratories Lederle, Pearl River, NY, 1989
74. Stewart DJ, Morgan LR, Verma S, et al: Pharmacology, relative bioavailability and toxicity of three different oral cyclophosphamide preparations in a randomized, cross over study. Invest New Drugs 13:99-107, 1995
75. Product Information, Matulane, Roche Pharmaceuticals, Nutley, NJ, 1994
76. Lee FYR, Workman P, Roberts JT, et al: Clinical pharmacokinetics of oral CCNU (lomustine). Cancer Chemother Pharmacol 14:125-131, 1985
77. Reece PA, Kotasek D, Morris RG, et al: The effect of food on oral melphalan absorption. Cancer Chemother Pharmacol 16:194-197, 1986
78. Knoben JE, Anderson PO (eds): Handbook of Clinical Drug Data (ed 6). Hamilton, IL, Drug Intelligence Publications, 1988
79. Hassan M, Oberg G, Ehrsson H, et al: Pharmacokinetic and metabolic studies of high-dose busulfan in adults. Eur J Clin Pharmacol 36:525-530, 1989
80. Ehrsson H, Hassan M, Ehrnebo M, et al: Busulfan kinetics. Clin Pharmacol Ther 34:86-89, 1983
81. McKeage MJ, Mistry P, Ward J, et al: A phase I and pharmacology study of on oral platinum complex, JM216: Dose-dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol 36:451-458, 1995
82. McKeage MJ, Raynaud, F, Ward J, et al: Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15:2691-2700, 1997
83. Raynaud FI., Mistry P, Donaghue A, et al: Biotransformation of the platinum drug JM-216 following oral administration to cancer patients. Cancer Chemother Pharmacol 38:155-162, 1996
84. Feigal EG, Christian M, Chesson B, et al: New chemotherapeutic agents in non small cell lung cancer. Semin Oncol 20:185-201, 1993
85. Zhou XJ, Bore P, Monjanel S, et al: Pharmacokinetics of navelbine after oral administration. Cancer Chemother Pharmacol 29:66-70, 1991
86. Creemers GL, Wanders J, Gamucci T, et al: Topotecan in colorectal cancer: A phase II study of the EORTC Early Clinical Trials Group. Ann Oncol 6:844-846, 1995 (suppl)
87. Creemers GL, Lund BJ, Verweijt J: Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 20:73-96, 1994
88. Schellens JHM, Creemers GJ, Beijnen JL, et al: Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor. Br J Cancer 73:1268-1271, 1996
89. Sparreboom A, Stoter G, Loos WJ, et al: Oral bioavailability of 9-aminocamptothecin in adult patients with solid tumors. Proc Am Assoc Cancer Res 38:75, 1007 (abstr 504)
90. Mani S, Iyer L, Janisch L, et al: Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (9-AC). Proc Am Soc Clin Oncol 16:201a, 1997 (abstr 706)
91. Au JL, Sadee W: Activation of ftorafur to 5-fluorouracil and gamma-butyrolactone. Cancer Res 40:2814-2819, 1980
92. Fujii S, Ikenaka K, Fukushima M, et al: Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Jpn J Cancer Res 69:763-772, 1978
93. Meropol NJ, Rustum YM, Petrelli NJ, et al: A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 37:581-586, 1996
94. Saltz LB, Leichman CG, Young CW, et al: A fixed-ratio combination of uracil and ftorafur (UFT. with low dose leucovorin: An active oral regimen for advanced colon cancer. Cancer 75:782-785, 1995
95. Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22:333-338, 1988
96. Pazdur R, Lassere Y, Rhodes V, et al: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2296-2300, 1994
97. Andersen E, Pedersen H: Oral ftorafur versus intravenous 5-fluorouracil: A comparative study in patients with colorectal cancer. Acta Oncol 26:433-436, 1987
98. Kono A, Hara Y, Sugata S, et al: Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 31:175-178, 1983
99. Ishitsuka H, Miwa M, Takemoto K, et al: Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine. Gann 71:112-123, 1980
100. Twelves C, Budman DR, Creaven, PJ, et al: Pharmacokinetics and pharmacodynamics of capecitabine in two phase I studies. Proc Am Soc Clin Oncol 16:476, 1996 (abstr 1509)
101. Schuller J, Cassidy J, Reigner BG, et al: Tumor selectivity of Xeloda in colorectal cancer patients. Proc Am Soc Clin Oncol 16:227, 1997 (abstr 797)
102. Findlay M, Van Cutsem E, Kocha W, et al: A randomised phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 16:227, 1997 (abstr 7)
103. Grem JL: Fluorinated pyrimidines, in Chabner BA, Collins JA (eds): Cancer Chemotherapy Priniciples and Practice. Philadelphia, PA, Lippincott, 1990, pp 180-224
104. Spector T, Harrington JA, Porter DJ: 5-Ethynyluracil (776C85): Inactivation of dihydropyridine dehydrogenase in vivo. Biochem Pharmacol 46:2243-2248, 1993
105. Baccanari DP, Davis ST, Knick VC et al: 776C85: Effects on the pharmacokinetics and antitumor activity of 5-fluorouracil. Proc Natl Acad Sci USA 90:11064-11068, 1993
106. Cao S, Rustum YM, Spector T: 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507-1510, 1994
107. Schilsky R, Bukowski R, Burris H, et al: A phase n study of a five day regimen of oral 5-fluorouracil (5-FU) plus GW776 (776C85) with or without leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 16:271a, 1997 (abstr 961)
108. McKeage MJ, Kelland LR, Boxall FE, et al: Schedule dependency of orally administered bis-aceto-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) in vivo. Cancer Res 54:4118-4122, 1994
109. Fujii H, Sasaki Y, Tamura T, et al: A phase I pharmacokinetic study of the oral platinum analogue JM216. Proc Am Soc Clin Oncol 16:215, 1997 (abstr 754)
110. Peerebom DM, Wood L, Connell J, et al: Phase II trial of oral BMS-182751 (JM-216) in hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 16:339, 1997 (abstr 1210)
111. McKeage MJ, Morgan SE, Boxall FE, et al: Lack of nephrotoxicity of oral ammine/amine platinum(IV) dicarboxylate complexes in rodents. Br J Cancer 67:996-1000, 1993
112. McKeage, MJ, Boxall F, Jones M, et al: Lack of neurotoxicity or oral bis-aceto-ammine- dichloro-cyclohexylamine-platinum (IV) (JM216) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 54:629-631, 1994
113. Groen HJM, Smit EF, Bauer J, et al: A phase II study of oral platinum JM-216 as a first line treatment in small cell lung cancer. Proc Am Soc Clin Oncol 15:378, 1996 (abstr 1128)
114. Judson I, Cerny T, Epelbaum R, et al: A phase II trail of oral platinum complex JM-216 in non-small-cell lung cancer: An EORTC Early Clinical Studies Group investigation. Ann Oncol 8:604-606, 1997
115. Wargin W, Lucas V: The clinical pharmacokinetics of vinorelbine (navelbine). Semin Oncol 21:21-27, 1994
116. Rowinsky E, Noe D, Trump D, et al: Pharmacokinetic, bioavailability and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 12:1754-1763, 1994
117. Vokes E, Rosenberg R, Jahanzeb M, et al: Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. J Clin Oncol 13:637-644, 1995
118. Winer E, O'Rourke M, Vogel C, et al: A US multicenter phase II trial of oral Navelbine in elderly women with advanced breast cancer. Breast Cancer Res Treat 27:136, 1993 (abstr 24)
119. Houghton PJ, Cheshire PJ, Hallman JD, et al: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts in human tumors. Cancer Chemother Pharamcol 36:393-403, 1995
120. McCabe FL, Johnson RK: Comparative activity of oral and parenteral topotecan in murine tumor models: Efficacy of oral topotecan. Cancer Invest 12:308-313, 1994
121. Schellens JHM, Creemers GJ, Beijnen JH, et al: Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase inhibitor. Br J Cancer 73:1268-1271, 1996
122. Gerrits C, Schellens J, Burris H, et al: Prolonged exposure to oral topotecan, correlates between pharmacokinetics and toxicity. Proc Am Soc Clin Oncol 16:224, 1997 (abstr 768)
123. Bissery MC, Vrignaud P, Lavelle F: Oral efficacy of irinotecan (CPT-11) in tumor bearing mice. Proc Am Assoc Cancer Res 38:74, 1997 (abstr 499)
124. Drengler R, Burris H, Dietz J, et al: A phase I trial to evaluate orally administered irinotecan HCl (CPT-11) given daily × 5 every 3 weeks in patients with refractory malignancies. Proc Am Soc Clin Oncol 15:489, 1996 (abstr 1560)
125. Toppmeyer D, Gupta E, Saleem A, et al: A phase I and pharmacodynamic study of camptothecin (CPT-11) and etoposide (E) in patients with advanced malignancies. Proc Am Soc Clin Oncol 16:203a, 1997 (abstr 713)
126. Yukawa E, Honda T, Shigehiro O, et al: Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. J Clin Pharmacol 37:92-100, 1997
127. Odani A, Hashimoto Y, Takayanagi K, et al: Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: Analysis with a dose-dependent clearance model. Biol Pharm Bull 19:444-448, 1996
128. Fujiwara Y, Ohune T, Okusaki K, et al: Bioavailability of 50 and 75 mg oral etoposide in lung cancer patients. Cancer Chemother Pharmacol 37:327-331, 1996